TOP TIERMARKET NEWSWIRE
News & sentiment

ARCUTIS BIOTHERAPEUT (ARQT) — News & AI sentiment

ARCUTIS BIOTHERAPEUT (ARQT) news roundup. 1 story in the past week, 5 over 30 days. Average 30-day sentiment is 54.4/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 11 sales totalling $2.1M — net selling of $2.1M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
1
avg sentiment 50/100
30d stories
5
avg sentiment 54.4/100
Insider net (90d)
$2.1M
0 buys · 11 sells
Congress (90d)
0
0 buys · 0 sells

ARQT news in the last 24 hours, 7 days, 30 days and 90 days

How much ARQT coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowARQT storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days150/100ARQT headlines →
Last 30 days554.4/100ARQT headlines →
Last 90 days3258/100ARQT headlines →

Latest stories on ARQT

Sep 4
Sep 4
Sep 4
Sep 2
Aug 20
Arcutis (ARQT) Q2 2026 Earnings Call Transcript
The Motley Fool73 · bullishearnings
Aug 12
Aug 12
Aug 7
Aug 7
Aug 6
Aug 6
Guggenheim raises Arcutis stock price target on strong Zoryve sales
Investing.com Analyst Ratings61 · neutralanalyst
Aug 6
Aug 6
Aug 6
Aug 5
Aug 5
Aug 5
Aug 5
Jul 29
Jul 23
Jul 17
Jul 16
Jul 16
Jul 9
Jul 8
Open ARQT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →